{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=10",
    "query": {
      "intervention": "Arm 1- Dose Escalation",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 959,
    "total_pages": 96,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Arm+1-+Dose+Escalation&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T11:28:58.252Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01744652",
      "title": "Dasatinib and Crizotinib in Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2013-03",
      "completion_date": "2019-03",
      "has_results": false,
      "last_update_posted_date": "2023-06-07",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01744652"
    },
    {
      "nct_id": "NCT04431635",
      "title": "Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Indolent Lymphoma"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2020-06-15",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2024-09-27",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 5,
      "location_summary": "Chicago, Illinois • Ann Arbor, Michigan • Omaha, Nebraska + 1 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04431635"
    },
    {
      "nct_id": "NCT04585035",
      "title": "Study to Evaluate D-1553 in Subjects With Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "NSCLC",
        "CRC"
      ],
      "interventions": [
        {
          "name": "D-1553",
          "type": "DRUG"
        },
        {
          "name": "D-1553 in combination with Drug: pembrolizumab, Drug:KEYTRUDA® , Drug: cetuximab, Drug: other",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "InventisBio Co., Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2020-10-02",
      "completion_date": "2025-12",
      "has_results": false,
      "last_update_posted_date": "2025-03-18",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 7,
      "location_summary": "Fresno, California • Orange, California • San Francisco, California + 4 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04585035"
    },
    {
      "nct_id": "NCT03711058",
      "title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor",
        "Microsatellite Stable (MSS) Colon Cancer"
      ],
      "interventions": [
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2019-01-17",
      "completion_date": "2025-06-30",
      "has_results": true,
      "last_update_posted_date": "2025-09-16",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03711058"
    },
    {
      "nct_id": "NCT07285148",
      "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer",
        "EGFR Mutation",
        "Metastatic Lung Cancer",
        "MET Alteration"
      ],
      "interventions": [
        {
          "name": "ANS014004 + PLB1004",
          "type": "DRUG"
        },
        {
          "name": "ANS014004 + Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beijing Pearl Biotechnology Limited Liability Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 253,
      "start_date": "2026-06",
      "completion_date": "2029-12",
      "has_results": false,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07285148"
    },
    {
      "nct_id": "NCT02158858",
      "title": "A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Myelofibrosis",
        "Leukemia, Myelocytic, Acute",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Myelodysplastic Syndrome (MDS)",
        "Preleukemia",
        "Primary Myelofibrosis",
        "Myeloproliferative Disorders",
        "Bone Marrow Disease",
        "Hematological Disease",
        "Precancerous Conditions",
        "Neoplasms",
        "Leukemia",
        "Neoplasms by Histologic Type",
        "Essential Thrombocytosis"
      ],
      "interventions": [
        {
          "name": "Pelabresib",
          "type": "DRUG"
        },
        {
          "name": "Ruxolitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Constellation Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2014-07-16",
      "completion_date": "2025-01-09",
      "has_results": true,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02158858"
    },
    {
      "nct_id": "NCT03090165",
      "title": "Ribociclib and Bicalutamide in AR+ TNBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "Bicalutamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kari Wisinski",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2018-05-07",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-01-02",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 6,
      "location_summary": "Chicago, Illinois • Lansing, Michigan • New Brunswick, New Jersey + 3 more",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Lansing",
          "state": "Michigan"
        },
        {
          "city": "New Brunswick",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03090165"
    },
    {
      "nct_id": "NCT02223598",
      "title": "A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoid Hematological Malignancies",
        "Relapsed and Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "CB-5083",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cleave Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2014-08-25",
      "completion_date": "2017-07-26",
      "has_results": false,
      "last_update_posted_date": "2018-02-27",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 6,
      "location_summary": "Duarte, California • San Francisco, California • Atlanta, Georgia + 3 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02223598"
    },
    {
      "nct_id": "NCT04909021",
      "title": "Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Respiratory Syncytial Virus (RSV)"
      ],
      "interventions": [
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 2)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; single-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Investigational RSV vaccine MV-012-968 (Dosage 3; two-dose)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (single-dose)",
          "type": "OTHER"
        },
        {
          "name": "Placebo (two-dose)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Meissa Vaccines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "36 Months",
        "sex": "ALL",
        "summary": "6 Months to 36 Months"
      },
      "enrollment_count": 63,
      "start_date": "2021-06-03",
      "completion_date": "2023-10",
      "has_results": false,
      "last_update_posted_date": "2022-08-02",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 12,
      "location_summary": "Phoenix, Arizona • La Mesa, California • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Idaho Falls",
          "state": "Idaho"
        },
        {
          "city": "Metairie",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04909021"
    },
    {
      "nct_id": "NCT05644587",
      "title": "Novel Induction to Buprenorphine/Naloxone",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Opioid Use Disorder",
        "Opioid Use",
        "Opioid Abuse",
        "Opioid Misuse",
        "Opioid Dependence"
      ],
      "interventions": [
        {
          "name": "buprenorphine/naloxone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bicycle Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2023-02-06",
      "completion_date": "2023-11-30",
      "has_results": false,
      "last_update_posted_date": "2024-08-20",
      "last_synced_at": "2026-11-15T11:28:58.252Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05644587"
    }
  ]
}